You are the owner of this article.
Village Board approves $3.2 million agreement to sell 16 acres to pharmaceutical company

Village Board approves $3.2 million agreement to sell 16 acres to pharmaceutical company

Nexus rendering

This rendering depicts Nexus Pharmaceuticals’ planned manufacturing facility, to be built in Pleasant Prairie.

PLEASANT PRAIRIE — The Village Board on Monday unanimously approved an agreement with Nexus Pharmaceuticals Inc., which plans to build a manufacturing plant in the village.

Nexus will buy 16 acres from the village in the Prairie Highlands Corporate Park for $3.2 million to construct the 100,000-square-foot plant, which is expected to break ground next month.

The proposed facility will be located in the northwest quadrant of Highway Q and 128th Avenue, west of Interstate 94, and would be the fourth tenant to occupy the corporate park.

Other firms announced for the park are international candy maker Haribo, Advocate Aurora Health and Center and OFFSITE, a Kenosha information technology firm that plans to expand to a new 250,000-square-foot data center campus in the corporate park.

Nexus Pharmaceuticals specializes in developing innovative processes to manufacture specialty and generic injectable drugs, according to village officials.

The facility will support the production and supply of injectable drugs for a variety of therapeutic areas including anesthesia, oncology, cardiovascular and neurology. Headquartered in Lincolnshire, Ill., Nexus is expanding its business to the village with the proposed manufacturing facility.

Nexus’ multi-phase, multi-year project is expected to be completed in 10 years.

Phase one construction is expected to be completed in 2021. Commercial production would begin in 2022.

According to the plans, the first phase will involve the construction of the $85 million, three-story manufacturing facility. The facility will house cutting-edge technology, including an advanced isolator system for maximum product protection and sterility, reducing the risk of contamination.

The facility will also include multiple freeze-drying machines to support production of the company’s current portfolio of generic and specialty injectable drugs. When manufacturing begins in 2022, Nexus expects to create 77 new jobs, with an average salary of about $70,000 annually.

“Our goal is to bring a lot of positive things to the community ... in the form of life-saving, generic injectable drugs. We know that’s important to not only Pleasant Prairie, Wisconsin, but to the United States as well,” said John Cook, vice president of manufacturing operations, who thanked the board and village staff.

Village Board President John Steinbrink thanked Cook and Nexus for selecting the village to develop a manufacturing facility.

“We’re so excited you chose Pleasant Prairie. This is a first,” he said.

Cook said the company “fell in love with the site.”

“It was a perfect fit. A perfect match,” he said. “We have great neighbors, and the community is fantastic. The folks that we met on day one, it was just connection. Nexus means a link, or connection, and we were confident that we had established that out of the gate.”

Board member Michael Pollocoff said that having the company come to the village is “an important step for the entire area.”

The board also voted unanimously to approved the developer’s agreement for infrastructure improvements within the tax incremental financing district for the project, guaranteeing $25 million in incremental development.

The agreement also contains a “forgivable” grant of $500,000 from the village to assist with site improvements, according to Village Administrator Nathan Thiel.

The grant comes with the condition that Nexus does not sell its business to another entity during the life of the tax incremental financing district.


Get Breaking News delivered directly to you.

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Nexus Pharmaceuticals is a U.S.-based healthcare company specializing in innovative processes that make difficult-to-manufacture specialty and…

Get up-to-the-minute news sent straight to your device.